IBJNews

Abatement approval paves way for Covance jobs

Back to TopCommentsE-mailPrintBookmark and Share

The Hancock County Council this morning unanimously approved a tax-incentive agreement that should lead Covance Inc. to add 315 jobs at its Greenfield Laboratories.

A spokeswoman for the New Jersey-based company earlier this month said abatement approval would seal Hancock County’s selection for the jobs over four other locations.

Covance plans to pay an average annual salary of $60,000, plus benefits, for jobs ranging from support staff and technicians to scientists and management.

Some of the jobs would support growth in Covance’s Biomarker Center of Excellence and such areas as nutritional chemistry and analytical services.

“That will just be huge,” Dennis Maloy, executive director of the Hancock County Economic Development Corp, said today. “These are the kinds of jobs all communities are trying to attract.”

Covance purchased the laboratories from Indianapolis-based Eli Lilly and Co. in August for $50 million and an agreement that Lilly would give Covance $1.6 billion worth of drug-development business over the next 10 years.

Covance offered jobs to all of the 260 employees who worked there and currently employs more than 300 at the labs.

The Greenfield site was one of Lilly’s oldest operations, dating to 1914.

Covance already employs 1,000 Hoosiers in Indianapolis and Evansville. Covance CEO Joe Herring told investors upon the purchase of the labs that the company hopes to land contracts with other drug companies and ramp up the 600,000-square-foot Greenfield facility to full capacity.

Lilly officials said the labs only operated at half their capacity.
 

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
ADVERTISEMENT